/
/
CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
A subscription to JoVE is required to view this content. Sign in or start your free trial.
8,172 Views
•
07:44 min
•
September 14, 2019
DOI:
Summary
Automatically generated
Here, we present a Cas9-based exon23 deletion protocol to restore dystrophin expression in iPSC from Dmdmdx mouse-derived skin fibroblasts and directly differentiate iPSCs into myogenic progenitor cells (MPC) using the Tet-on MyoD activation system.
Read Article
Cite this Article
Jin, Y., Shen, Y., Su, X., Weintraub, N., Tang, Y. CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors. J. Vis. Exp. (151), e59432, doi:10.3791/59432 (2019).
Copy